ImmunoGen Inc.
About ImmunoGen Inc.
ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology. The Company's lead product candidate, mirvetuximab soravtansine, is being advanced to Phase 3 testing for FRα-positive platinum-resistant ovarian cancer, and is also in Phase 1b/2 testing in combination regimens for earlier-stage disease. The Company's ADC technology is used in three other clinical-stage ImmunoGen product candidates, in Roche's marketed product, Kadcyla®, and in programs in development by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda.
442 articles with ImmunoGen Inc.
-
ImmunoGen Reports Recent Progress and Second Quarter 2019 Financial Results
8/2/2019
ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, reviewed recent progress in the business and reported financial results for the quarter ended June 30, 2019.
-
ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2019 Operating Results
7/18/2019
ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, August 2, 2019 to discuss its second quarter operating results.
-
ImmunoGen Announces Completion of Operational Review
6/27/2019
Company Will Prioritize Continued Development of Mirvetuximab Soravtansine and a Select Portfolio of Earlier-Stage Candidates
-
Following an operational review, ImmunoGen will prioritize continued development of mirvetuximab, as well as a select portfolio of three earlier-stage product candidates.
-
Here's a roundup of some of the top clinical trial news from the previous week.
-
ImmunoGen Announces Mature Data from FORWARD II Expansion Cohort Evaluating Mirvetuximab Soravtansine in Combination with Avastin® in Ovarian Cancer
5/15/2019
ImmunoGen, Inc. announced mature data from the FORWARD II expansion cohort evaluating mirvetuximab soravtansine in combination with Avastin® in patients with folate receptor alpha-positive platinum-resistant ovarian cancer.
-
Good, but Not Good Enough: FDA Urges ImmunoGen to Run Another Phase III Trial for Ovarian Cancer ...
5/15/2019
The FDA told the company that the results from the trial didn’t meet its primary endpoint under the pre-specified statistical analysis plan and the data around the secondary endpoints couldn’t be used to support an accelerated approval application. -
ImmunoGen Reports Recent Progress and First Quarter 2019 Financial Results
5/3/2019
ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended March 31, 2019.
-
ImmunoGen Announces Conference Call to Discuss Its First Quarter 2019 Operating Results
4/18/2019
ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, May 3, 2019
-
ImmunoGen Announces Top-Line Results from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer
3/1/2019
ImmunoGen, Inc. announced that its Phase 3 FORWARD I trial evaluating the safety and efficacy of mirvetuximab soravtansine compared to chemotherapy in patients with folate receptor alpha (FRα)-positive, platinum-resistant ovarian cancer did not meet its primary endpoint of progression-free survival (PFS) in either the entire study population or in the pre-specified subset of patients with high FRα expression.
-
ImmunoGen’s FORWARD I trial was testing the safety and efficacy of mirvetuximab soravtansine compared to chemotherapy in patients with folate receptor alpha (FRα)-positive, platinum-resistant ovarian cancer.
-
ImmunoGen Announces Multiple Presentations at AACR Annual Meeting
2/27/2019
First-in-Class ADAM9-targeting ADC, IMGC936, Developed in Collaboration with MacroGenics, Demonstrates Preclinical Activity in Models of Non-Small Cell Lung, Gastric, and Colorectal Cancers
-
ImmunoGen Reports Recent Progress and 2018 Operating Results
2/8/2019
Top-Line Data from Phase 3 FORWARD I Mirvetuximab Soravtansine Study on Track for First Half of 2019
-
ImmunoGen Announces Conference Call to Discuss Its 2018 Operating Results
1/24/2019
ImmunoGen Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, February 8, 2019 to discuss its 2018 operating results.
-
ImmunoGen Announces Sale of Residual Kadcyla Royalties
1/8/2019
ImmunoGen, Inc. today announced the sale of its residual rights to receive royalty payments on commercial sales of Kadcyla® (ado-trastuzumab emtansine) to OMERS
-
ImmunoGen Announces Webcast of Presentation and Q&A at the 37th Annual J.P. Morgan Healthcare Conference
1/2/2019
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, President and CEO, will present at the upcoming 37th Annual J.P. Morgan Healthcare Conference in San Francisco.
-
ImmunoGen Presents New Data Highlighting Potential of Novel ADCs in Oral Presentations at ASH Annual Meeting
12/1/2018
ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that new data from the ongoing Phase 1 studies of IMGN632 and IMGN779, next-generation CD123- and CD33-targeting ADCs
-
ImmunoGen Announces Resignation of Chief Financial Officer
11/26/2018
ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that David B. Johnston has stepped down as Chief Financial Officer of the Company, with immediate effect
-
Over 76 Data Driven Presentations on Cancer Treatment Research to be Presented at the 9th Annual World Antibody-Drug Conjugate Conference in San Diego, November 12-15
11/8/2018
The Antibody-Drug Conjugate community will join together for the 9th World ADC San Diego on November 12-15 at the Marriott Marquis San Diego with key influential researchers from around the world, to discuss clinical research experiences to help further the development of cancer therapeutics.
-
ImmunoGen Announces Webcasts of Presentations at Upcoming November 2018 Conferences
11/6/2018
ImmunoGen, Inc. today announced that the following presentations by Company management at upcoming investor conferences will be webcast: